A 2016 study in 36 GH secreting PitNET cases, using exome sequencing, observed similar conclusions: a median of three protein-altering somatic variants per tumor (range: 0–13), recurrent GNAS variants, no other shared genetic variants between samplesor with samples of previous smaller scale research [21]. This evidence concerns the gene GH1 and neoplasm.